Acute-type acquired hemophilia A after COVID-19 mRNA vaccine administration: A new disease entity?

ElsevierVolume 133, December 2022, 102915Journal of AutoimmunityHighlights•

COVID-19 mRNA vaccines may cause acquired hemophilia A (AHA), even in young patients.

In young patients, mRNA COVID-19 vaccine-related AHA may resolve spontaneously.

Similar to immune thrombocytopenic purpura, such AHA cases may involve acute disease.

Abstract

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder. Various autoimmune diseases, including AHA, have been reported to occur after the administration of mRNA COVID-19 vaccines. However, the characteristics of these AHA cases remain unclear. We report a case in which AHA arose in a young patient after the administration of an mRNA COVID-19 vaccine, but improved rapidly. The patient's factor VIII (FVIII) inhibitor titer spontaneously decreased to less than half of that seen at diagnosis. One week after the initial immunosuppressive therapy, the FVIII inhibitor had disappeared. Our case suggests that AHA that arises in young patients after COVID-19 vaccination may resolve spontaneously, and the levels of FVIII inhibitors may decrease more rapidly in such cases than in idiopathic AHA. Unlike for immune thrombocytopenic purpura (ITP), no acute type of AHA has been recognized. This case suggests that just as there is an acute type of ITP that develops in children/after vaccination, there may be an acute type of AHA that arises in young patients that receive mRNA COVID-19 vaccines.

Keywords

COVID-19

Vaccination

Acquired hemophilia A

View Abstract

© 2022 Elsevier Ltd. All rights reserved.

留言 (0)

沒有登入
gif